Działania niepożądane oraz interakcje wybranych leków kardiologicznych stosowanych w terapii niewydolności serca Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2009
Słowa kluczowe:
działania niepożądane, niewydolność serca, polipragmazja
##plugins.themes.bootstrap3.article.main##
Abstrakt
Działania niepożądane (ADR, Adverse Drug Reaction) odnotowywane są często we współczesnej praktyce klinicznej, powodują wzrost zachorowalności i śmiertelności wśród pacjentów, a ponadto generują niepotrzebne koszty leczenia. Pacjenci ze schorzeniami kardiologicznymi są grupą szczególnie narażoną na występowanie ADR ze względu na zaawansowany wiek, politerapię oraz sam wpływ chorób serca na metabolizm leków. Złożone interakcje, występujące pomiędzy pacjentem, lekiem a chorobą, to słabo jak dotąd poznany obszar wiedzy, co w istotny sposób przekłada się na bezpieczeństwo i skuteczność terapii. Większość działań niepożądanych, które wywołują preparaty kardiologiczne, jest przewidywalna, a przez to możliwa do uniknięcia. Edukowanie pacjenta w tym zakresie, unikanie wielolekowej terapii oraz lepsza komunikacja między lekarzem, farmaceutą i pacjentem, szczególnie podczas przechodzenia chorego z etapu hospitalizacji do dalszego leczenia ambulatoryjnego, wpływa zasadniczo na redukcję ryzyka występowania działań niepożądanych.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
Zaremba, M., & Postuła , M. (2009). Działania niepożądane oraz interakcje wybranych leków kardiologicznych stosowanych w terapii niewydolności serca. Kardiologia W Praktyce, 3(3), 110-117. Pobrano z https://www.journalsmededu.pl/index.php/kwp/article/view/1654
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. International drug monitoring: the role of national centres. Report of a WHO meeting. World Health Organ Tech. Rep. Ser. 1972, 498: 1-25.
2. Lazarou J., Pomeranz B.H., Corey P.N.: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998, 279: 1200-5.
3. Pirmohamed M., Breckenridge A.M., Kitteringham N.R., Park B.K.: Adverse drug reactions. BMJ 1998, 316: 1295-8.
4. Pirmohamed M., Breckenridge A.M., Kitteringham N.R., Park B.K.: Adverse drug reactions. BMJ 1998, 316: 1295-8.
5. Woosley R.L.: Pharmacokinetics and pharmacodynamics of antiarrhythmic agents in patients with congestive heart failure. Am. Heart J. 1987, 114: 1280-91.
6. Rawlins M.D., Thompson J.W.: Pathogenesis of adverse drug reactions. W: DM Textbook of Adverse Drug Reactions. Davies D.M. (red.). Oxford University Press, Oxford 1981.
7. Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology, Dickstein K., Cohen-Solal A., Filippatos G. et al.: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur. Heart J. 2008, 29: 2388-2442.
8. Croft J.B., Giles W.H., Pollard R.A. et al.: Heart failure survival among older adults in the United States: a poor prognosis for an emerging epidemic in the Medicare population. Arch. Intern. Med. 1999, 159: 505-10.
9. Pitt B., Zannad F., Remme W.J. et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 1999, 341: 709-17.
10. Pitt B., Remme W., Zannad F. et al.: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003, 348: 1309-21.
11. Juurlink D.N., Mamdani M.M., Lee D.S. et al.: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. 2004, 351: 543-51.
12. McMurray J.J., Ostergren J., Swedberg K. et al.: Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362: 767-71.
13. Eichhorn E.J.: The paradox of beta-adrenergic blockade for the management of congestive heart failure. Am. J. Med. 1992, 92: 527-38.
14. Waagstein F.: Beta blockers in heart failure. Cardiology 1993, 82: 13-8.
15. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353: 9-13.
16. Packer M., Fowler M.B., Roecker E.B. et al.: Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002, 106: 2194-9.
17. Hjalmarson A., Goldstein S., Fagerberg B. et al.: Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000, 283: 1295-302.
18. Poole-Wilson P.A., Swedberg K., Cleland J.G. et al.: Comparison of carvedilol and metoprololon clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003, 362: 7-13.
19. Werner D., Wuttke H., Fromm M.F.: Effect of amiodarone on the plasma levels of metoprolol. Am. J. Cardiol. 2004, 94: 1319-1321.
20. Zipes D.P., Camm A.J., Borggrefe M. et al.: ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J. Am. Coll. Cardiol. 2006, 48: 247-346.
21. Peacock W.F., Fonarow G.C., Emerman C.L. et al.: Impact of early initiation of intravenous therapy for acute decompensated heart failure on outcomes in ADHERE. Cardiology 2007, 107: 44-51.
22. The SOLVD Investigators: Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 1991, 325: 293-302.
23. Flather M., Yusuf S., Kober L. et al.: Long-term ACE-inhibitor therapy in patients with heart failure of left-ventricular dysfunction – a systematic overview of data from individual patients. ACE-inhibitor Myocardial Infaction Collaborative Group. Lancet 2000, 355: 1575-81.
24. CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N. Engl. J. Med. 1987, 316: 1429-35.
25. McMurray J., Cohen-Solal A., Dietz R. et al.: Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. Eur. J. Heart Fail. 2005, 7: 710-21.
26. Silver P.J., Harris A.L., Canniff P.C. et al.: Phosphodiesterase isozyme inhibition, activation of the cAMP system, and positive inotropy mediated by milrinone in isolated guinea pig cardiac muscle. J. Cardiovasc. Pharmacol. 1989, 13: 530-40.
27. Packer M., Carver J.R., Rodeheffer R.J. et al.: Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N. Engl. J. Med. 1991, 325: 1468-75.
28. O’Connor C.M., Gattis W.A., Uretsky B.F. et al.: Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am. Heart J. 1999, 138: 78-86.
29. El-Sayed, Abdelfattah R.R., Barcelona R., Leier C.V.: Dobutamine- induced eosinophilia. Am. J. Cardiol. 2004, 93: 1078-9.
30. Pitt B., Goldstein S.: The captopril-digoxin multicenter resarch group study on the comparative steps of captopril and digoxin in patients with mildmoderate heart failure: Implications for therapy. J. Cardiovasc. Drugs Therapy 1989, 3: 7-9.
31. Adams K.F. Jr., Patterson J.H., Gattis W.A. et al.: Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J. Am. Coll. Cardiol. 2005, 46: 497-504.
32. Dick M., Curwin J., Tepper D.: Digitalis intoxication recognition and management. J. Clin. Pharmacol. 1991, 31: 444.
33. Taboulet P., Baud F.J., Bismuth C., Vicaut E.: Acute digitalis intoxication: Is pacing still appropriate? J. Toxicol. Clin. Toxicol. 1993, 31: 261.
34. Woolf A.: Revising the management of digitalis poisoning. J. Toxicol. Clin. Toxicol. 1993, 31: 275.
35. Varriole P., Mossari A.: Rapid reversal of digitalis delirium using digoxin immune Fab therapy. Clin. Cardiol. 1995, 18: 351.
36. Kurowski V., Iven H., Djonlagic H.: Treatment of a patient with severe digitoxin intoxication by Fab fragments of antidigitalis antibodies. Intensive Care Med. 1992, 18: 439.
37. Antman E.M., Wenger T.L., Butler V.P. et al.: Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments Final report of a multicenter study. Circulation 1990, 81: 1744-52.
38. Alam A.N., Saha J.R., Dobkin J.F. et al.: Interethnic variation in the metabolic inactivation of digoxin by the gut flora. Gastroenterology 1988, 95: 117-23.
39. Faulx M.D., Francis G.S.: Adverse drug reactions in patients with cardiovascular disease. Curr. Probl. Cardiol. 2008, 33: 703-768.
2. Lazarou J., Pomeranz B.H., Corey P.N.: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998, 279: 1200-5.
3. Pirmohamed M., Breckenridge A.M., Kitteringham N.R., Park B.K.: Adverse drug reactions. BMJ 1998, 316: 1295-8.
4. Pirmohamed M., Breckenridge A.M., Kitteringham N.R., Park B.K.: Adverse drug reactions. BMJ 1998, 316: 1295-8.
5. Woosley R.L.: Pharmacokinetics and pharmacodynamics of antiarrhythmic agents in patients with congestive heart failure. Am. Heart J. 1987, 114: 1280-91.
6. Rawlins M.D., Thompson J.W.: Pathogenesis of adverse drug reactions. W: DM Textbook of Adverse Drug Reactions. Davies D.M. (red.). Oxford University Press, Oxford 1981.
7. Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology, Dickstein K., Cohen-Solal A., Filippatos G. et al.: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur. Heart J. 2008, 29: 2388-2442.
8. Croft J.B., Giles W.H., Pollard R.A. et al.: Heart failure survival among older adults in the United States: a poor prognosis for an emerging epidemic in the Medicare population. Arch. Intern. Med. 1999, 159: 505-10.
9. Pitt B., Zannad F., Remme W.J. et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 1999, 341: 709-17.
10. Pitt B., Remme W., Zannad F. et al.: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003, 348: 1309-21.
11. Juurlink D.N., Mamdani M.M., Lee D.S. et al.: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. 2004, 351: 543-51.
12. McMurray J.J., Ostergren J., Swedberg K. et al.: Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362: 767-71.
13. Eichhorn E.J.: The paradox of beta-adrenergic blockade for the management of congestive heart failure. Am. J. Med. 1992, 92: 527-38.
14. Waagstein F.: Beta blockers in heart failure. Cardiology 1993, 82: 13-8.
15. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353: 9-13.
16. Packer M., Fowler M.B., Roecker E.B. et al.: Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002, 106: 2194-9.
17. Hjalmarson A., Goldstein S., Fagerberg B. et al.: Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000, 283: 1295-302.
18. Poole-Wilson P.A., Swedberg K., Cleland J.G. et al.: Comparison of carvedilol and metoprololon clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003, 362: 7-13.
19. Werner D., Wuttke H., Fromm M.F.: Effect of amiodarone on the plasma levels of metoprolol. Am. J. Cardiol. 2004, 94: 1319-1321.
20. Zipes D.P., Camm A.J., Borggrefe M. et al.: ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J. Am. Coll. Cardiol. 2006, 48: 247-346.
21. Peacock W.F., Fonarow G.C., Emerman C.L. et al.: Impact of early initiation of intravenous therapy for acute decompensated heart failure on outcomes in ADHERE. Cardiology 2007, 107: 44-51.
22. The SOLVD Investigators: Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 1991, 325: 293-302.
23. Flather M., Yusuf S., Kober L. et al.: Long-term ACE-inhibitor therapy in patients with heart failure of left-ventricular dysfunction – a systematic overview of data from individual patients. ACE-inhibitor Myocardial Infaction Collaborative Group. Lancet 2000, 355: 1575-81.
24. CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N. Engl. J. Med. 1987, 316: 1429-35.
25. McMurray J., Cohen-Solal A., Dietz R. et al.: Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. Eur. J. Heart Fail. 2005, 7: 710-21.
26. Silver P.J., Harris A.L., Canniff P.C. et al.: Phosphodiesterase isozyme inhibition, activation of the cAMP system, and positive inotropy mediated by milrinone in isolated guinea pig cardiac muscle. J. Cardiovasc. Pharmacol. 1989, 13: 530-40.
27. Packer M., Carver J.R., Rodeheffer R.J. et al.: Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N. Engl. J. Med. 1991, 325: 1468-75.
28. O’Connor C.M., Gattis W.A., Uretsky B.F. et al.: Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am. Heart J. 1999, 138: 78-86.
29. El-Sayed, Abdelfattah R.R., Barcelona R., Leier C.V.: Dobutamine- induced eosinophilia. Am. J. Cardiol. 2004, 93: 1078-9.
30. Pitt B., Goldstein S.: The captopril-digoxin multicenter resarch group study on the comparative steps of captopril and digoxin in patients with mildmoderate heart failure: Implications for therapy. J. Cardiovasc. Drugs Therapy 1989, 3: 7-9.
31. Adams K.F. Jr., Patterson J.H., Gattis W.A. et al.: Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J. Am. Coll. Cardiol. 2005, 46: 497-504.
32. Dick M., Curwin J., Tepper D.: Digitalis intoxication recognition and management. J. Clin. Pharmacol. 1991, 31: 444.
33. Taboulet P., Baud F.J., Bismuth C., Vicaut E.: Acute digitalis intoxication: Is pacing still appropriate? J. Toxicol. Clin. Toxicol. 1993, 31: 261.
34. Woolf A.: Revising the management of digitalis poisoning. J. Toxicol. Clin. Toxicol. 1993, 31: 275.
35. Varriole P., Mossari A.: Rapid reversal of digitalis delirium using digoxin immune Fab therapy. Clin. Cardiol. 1995, 18: 351.
36. Kurowski V., Iven H., Djonlagic H.: Treatment of a patient with severe digitoxin intoxication by Fab fragments of antidigitalis antibodies. Intensive Care Med. 1992, 18: 439.
37. Antman E.M., Wenger T.L., Butler V.P. et al.: Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments Final report of a multicenter study. Circulation 1990, 81: 1744-52.
38. Alam A.N., Saha J.R., Dobkin J.F. et al.: Interethnic variation in the metabolic inactivation of digoxin by the gut flora. Gastroenterology 1988, 95: 117-23.
39. Faulx M.D., Francis G.S.: Adverse drug reactions in patients with cardiovascular disease. Curr. Probl. Cardiol. 2008, 33: 703-768.